Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chun-Xiao Chang"'
Publikováno v:
OncoTargets and therapy
Bin Zhang,1,* Rui Li,2,3,* Chun-Xiao Chang,2,3 Yong Han,2,3 Sheng-Bin Shi,2,3 Jing Tian2,3 1Department of Medical Oncology, Shandong Ji Ning First People’s Hospital, 2Department of Medical Oncology, Shandong Cancer Hospital, Shandong University, Sh
Publikováno v:
Translational research : the journal of laboratory and clinical medicine. 170
This study was conducted to evaluate microRNAs (miRNAs) as biomarkers for use in predicting the efficacy of maintenance therapy with pemetrexed in patients with stage IIIb or IV lung adenocarcinoma and who had already received first-line treatment wi
Autor:
Zhe-Hai Wang, Jie Li, Li-Sheng Liu, Xin-Ping Sun, Chun-Xiao Chang, Jun Guo, Kan Zhai, Yong Huang, Hui Zhu, Huihui Li
Publikováno v:
Scientific Reports
Tumour necrosis factor-α (TNF-α) is critical in the regulation of inflammation and tumour progression. TNF-α-308G > A is associated with constitutively elevated TNF-α expression. The purpose of this study was to assess the association between TNF
Autor:
Jie-Lin Qi, Xiao-Yong Tang, Chun-Xiao Chang, Sheng-Bin Shi, Jing Tian, Rong-Hang Hu, Guo-Fang Liu
Publikováno v:
Medical Oncology. 31
The aim of this study was to determine the efficacy and toxicity of pemetrexed plus dendritic cells (DCs) in patients suffering from stage IIIB or IV lung adenocarcinoma, who had undergone maintenance treatment with gefitinib or erlotinib. Patients w
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 37(4)
The aim of this study was to evaluate the safety and effectiveness of erlotinib plus DC/CIK in maintenance therapy of advanced non-small cell lung cancer. After 4 cycles of the 2-drug regimen treatment with platinum, the 54 patients with non-small ce
Publikováno v:
Medical Oncology (Northwood, London, England)
To determine the efficacy and toxicity of Pemetrexed plus Oxaliplatin in patients suffering from stage IIIb or IV lung adenocarcinoma and being treated with Erlotinib as second-line treatment, a total of 45 patients were randomly divided into two gro
Publikováno v:
OncoTargets & Therapy; Jun2016, Vol. 9, p3901-3906, 6p